XL147: Updated Phase Ib/II data

Updated data from 22 patients in an ongoing, open-label, dose-escalation, U.S. Phase Ib/II trial showed that once-daily oral XL147 in combination with paclitaxel and carboplatin produced 1 complete response and 4 partial responses in patients previously treated with a platinum-containing chemotherapy regimen. The MTD has not been reached. Patients received up to 600 mg once-daily XL147 plus paclitaxel and carboplatin on day 1 in 21-day cycles. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...